A fatty acid oxidation-dependent metabolic shift regulates the adaptation of BRAF-mutated melanoma to MAPK inhibitors

PURPOSE: Treatment of BRAF(V600E)-mutant melanomas with mitogen-activated protein kinase inhibitors (MAPKi) results in significant tumor regression, but acquired resistance is pervasive. To understand non-mutational mechanisms underlying the adaptation to MAPKi and to identify novel vulnerabilities...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Cancer Res
Hauptverfasser: Aloia, Andrea, Müllhaupt, Daniela, Chabbert, Christophe D., Eberhart, Tanja, Flückiger-Mangual, Stefanie, Vukolic, Ana, Eichhoff, Ossia, Irmisch, Anja, Alexander, Leila T., Scibona, Ernesto, Frederick, Dennie T., Miao, Benchun, Tian, Tian, Cheng, Chaoran, Kwong, Lawrence N., Wei, Zhi, Sullivan, Ryan J., Boland, Genevieve M., Herlyn, Meenhard, Flaherty, Keith T., Zamboni, Nicola, Dummer, Reinhard, Zhang, Gao, Levesque, Mitchell P., Krek, Wilhelm, Kovacs, Werner J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2019
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6906212/
https://ncbi.nlm.nih.gov/pubmed/31375515
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-0253
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge